Completed
BisphosphonateEfficacy and Safety on the Use of Bisphosphonates in Paediatrics
What is being collected
Data Collection
Collected from past medical records and data - RetrospectiveWho is being recruted
Bone Diseases+6
+ Jaw Diseases
+ Stomatognathic Diseases
Until 18 Years
+3 Eligibility Criteria
How is the trial designed
Cohort
Tracking disease incidence in order to identify risk factors and understand disease progression over time.Observational
Study Start: October 2018
Summary
Principal SponsorCentre Hospitalier Universitaire de Nīmes
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Study start date: October 31, 2018
Actual date on which the first participant was enrolled.The investigators suppose that the impact of bisphosphonate therapy is beneficial on the bone during the growth period with few adverse events.
Official TitleEfficacy and Safety on the Use of Bisphosphonates in Paediatrics
Principal SponsorCentre Hospitalier Universitaire de Nīmes
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
99 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Cohort
These studies follow a group of individuals with common characteristics (such as a condition or birth year) over a specific period to study health outcomes or exposures.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Until 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Bone DiseasesJaw DiseasesStomatognathic DiseasesMusculoskeletal DiseasesNecrosisOsteonecrosisPathologic ProcessesPathological Conditions, Signs and SymptomsBisphosphonate-Associated Osteonecrosis of the Jaw
Criteria
2 inclusion criteria required to participate
be under 18 years of age
have been treated by intravenous bisphosphonates for primary or secondary osteoporosis
1 exclusion criteria prevent from participating
be over 18 years of age
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Study Objectives
Study Objectives
Primary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Suspended
CompletedOne Study Center